Skip to content

Study of Ayurvedic medicine Yavasa in the treatment of Gout.

Phytochemical Analysis and Therapeutic Evaluation Of Yavasa Alhagi camelorum DC In The Management Of Vatarakta Gout - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113825
Enrollment
30
Registered
2026-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M100- Idiopathic gout

Interventions

None listed

Sponsors

Ayurvedic and Unani tibbia college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a Patients belong to the age group of 21 - 65 years of irrespective of their sex religion caste. b Patients having the classical features of Vatarakta such as Shula Saruka Shotha Raga Kandu, Vidaha Sparshasahishnutha etc. c Serum Uric Acid level for male more than 7mg per dl and for female more than 6mg per dl. d Patients willing to participate in the trial and give written informed consent.

Exclusion criteria

Exclusion criteria: a Serum Uric Acid more than 10 mg per dl. b Patients already diagnosed with any other inflammatory joint disorders like Rheumatoid arthritis Osteoarthritis. c Patients suffering from Chronic Renal impairment Chronic Respiratory diseases Hepatic disease etc. d Pregnant and Lactating patients. e Patients taking Steroid therapy more than 6 weeks. f Patients taking any form of medication for Hyperuricemia. g Patients with Uncontrolled diabetes HbA1c nore than 7 As per WHO

Design outcomes

Primary

MeasureTime frame
The Expected Primary End point is improvement in the serum uric acid from baseline Day 1 after 90 days of intervention.Timepoint: The Expected Primary End point is improvement in the serum uric acid from baseline Day 1 after 90 days of intervention.

Secondary

MeasureTime frame
To confirm the collected Yavasa samples meets official API standards ensuring its quality and medicinal authenticity. The Expected secondary outcome is the safety and efficacy of the therapy under investigation. Safety will be assessed based on the adverse events recorded during the study. Timepoint: 3 months

Countries

India

Contacts

Public ContactBanshidhar Behera

Ayurvedic and unani tibbia college

drbanshi@rediffmail.com9414458895

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026